Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05233228Phase 2Recruiting
Phase 2, randomised, open-label trial (2 arms), sponsored by University of Oklahoma. Primary endpoints: Biochemically confirmed self-reported 7-day point prevalence abstinence at 12 months and Smoking status at 3 months post-enrollment. Started Apr 2022; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05233228.